Premium
Ever since the Maharashtra drug regulator filed a police case against online retailer Snapdeal in 2015 for selling prescription drugs, regulatory uncertainty has continued to hound the e-pharmacy market in India. The latest salvo has been fired by the Drug Controller General of India (DCGI), the country’s pharmaceutical regulator. On November ......
This is a Premium article. Please subscribe or log in to read the full story!
Here's a selection of our recent premium content.
Already a member? Click here to log in.
